Genetic and epigenetic heterogeneity in cancer: A genome-centric perspective

Journal of Cellular Physiology

Volumn 220, Issue 3, 2009, Pages 538-547

  Heng, Henry H Q ^a   Bremer, Steven W ^a   Stevens, Joshua B ^a   Ye, Karen J ^b   Liu, Guo ^a   Ye, Christine J ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SeeDNA Biotech Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; PROTEIN P53;

ACETYLATION; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER GROWTH; CANCER RESEARCH; CARCINOGENICITY; CONCEPTUAL FRAMEWORK; CONTROLLED STUDY; CYTOGENETICS; EPIGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUNCTION; GENE MUTATION; GENETIC HETEROGENEITY; GENOME; GENOME ANALYSIS; GENOMIC INSTABILITY; KARYOTYPE; KARYOTYPING; MELANOMA; METHYLATION; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; MOLECULAR MECHANICS; NATURAL SELECTION; NEOPLASM; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN PROCESSING; SHORT SURVEY; SIGNAL NOISE RATIO; STOCHASTIC MODEL; TUMOR GENE; UBIQUITINATION; BIOLOGICAL MODEL; CELL TRANSFORMATION; CHROMOSOME ABERRATION; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; GENOMICS; HUMAN; HUMAN GENOME; MUTATION; PATHOLOGY; PHENOTYPE; POPULATION GENETICS; REVIEW;

CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; EPIGENESIS, GENETIC; EVOLUTION, MOLECULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION TO DISEASE; GENETICS, POPULATION; GENOME, HUMAN; GENOMICS; HUMANS; KARYOTYPING; MODELS, GENETIC; MUTATION; NEOPLASMS; PHENOTYPE;

EID: 67650376000     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21799     Document Type: Short Survey

References (93)

1. Albertson DG, Collins C, McCormick F, Gray JW. 2003. Chromosome aberrations in solid tumors. Nat Genet 34:369-376.
2. Ao P. 2009. Global view of bionetwork dynamics: Adaptive landscape. J Genet Genomics 36:63-73.
3. Aubele M, Mattis A, Zitzelsberger H, Walch A, Kremer M, Hutzler P, Höfler H, Werner M. 1999. Intratumoral heterogeneity in breast carcinoma revealed by laser-microdissection and comparative genomic hybridization. Cancer Genet Cytogenet 110:94-102.
4. Bartos JD, Gaile DP, McQuaid DE, Conroy JM, Darbary H, Nowak NJ, Block A, Petrelli NJ, Mittelman A, Stoler DL, Anderson GR. 2007. a CGH local copy number aberrations associated with overall copy number genomic instability in colorectal cancer: Coordinate involvement of the regions including BCR and ABL. Mutat Res 615:1-11.
5. Bayani J, Selvarajah S, Maire G, Vukovic B, Al-Romaih K, Zielenska M, Squire JA. 2007. Genomic mechanisms and measurement of structural and numerical instability in cancer cells. Semin Cancer Biol 17:5-18.
6. Baylin SB. 2005. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 1:S4-11.
7. Bernstein BE, Meissner A, Lander ES. 2007. The mammalian epigenome. Cell 128:669-681.
8. Bielas JH, Loeb KR, Rubin BP, True LD, Loeb LA. 2006. Human cancers express a mutator phenotype. Proc Natl Acad Sci USA 103:18238-18242.
9. Bissell MJ, Kenny PA, Radisky DC. 2005. Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: The role of extracellular matrix and its degrading enzymes. Cold Spring Harb Symp Quant Biol 70:343-356.
10. Calin GA, Liu CG, Ferracin M, Hyslop T, Spizzo R, Sevignani C, Fabbri M, Cimmino A, Lee EJ, Wojcik SE, Shimizu M, Tili E, Rossi S, Taccioli C, Pichiorri F, Liu X, Zupo S, Herlea V, Gramantieri L, Lanza G, Alder H, Rassenti L, Volinia S, Schmittgen TD, Kipps TJ, Negrini M, Croce CM. 2007. Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell 12:215-229.
11. Campbell LL, Polyak K. 2007. Breast tumor heterogeneity: Cancer stem cells or clonal evolution? Cell Cycle 6:2332-2338.
12. Cokus SJ, Feng S, Zhang X, Chen Z, Merriman B, Haudenschild CD, Pradhan S, Nelson SF, Pellegrini M, Jacobsen SE. 2008. Shotgun bisulphite sequencing of the Arabidopsis genome reveals DNA methylation patterning. Nature 452:215-219.
13. Collins FS, Barker AD. 2007. Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. Sci Am 296:50-57.
14. Delcuve GP, Rastegar M, Davie JR. 2009. Epigenetic control. J Cell Physiol 219:243-250.
15. Dexter DL, Kowalski HM, Blazar BA, Fligiel Z, Vogel R, Heppner GH. 1978. Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res 38:3174-3181.
16. Dolinoy DC, Jirtle RL. 2008. Environmental epigenomics in human health and disease. Environ Mol Mutagen 49:4-8.
17. Duesberg P, Li R, Fabarius A, Hehlmann R. 2006. Aneuploidy and cancer: From correlation to causation. Contrib Microbiol 13:16-44.
18. Dunn KL, He S, Wark L, Delcuve GP, Sun JM, Yu Chen H, Mai S, Davie JR. 2009. Increased genomic instability and altered chromosomal protein phosphorylation timing in HRAS-transformed mouse fibroblasts. Genes Chromosomes Cancer 48:397-409.
19. Esteller M. 2008. Epigenetics in cancer. N Engl J Med 358:1148-1159.
20. Feinberg AP, Ohlsson R, Henikoff S. 2006. The epigenetic progeneitor origin of human cancer. Nat Rev Genet 7:21-32.
21. Foulds L. 1954. The experimental study of tumor progression: A review. Cancer Res 14:327-399.
22. Fujii H, Szumel R, Marsh C, Zhou W, Gabrielson E. 1996. Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast. Cancer Res 56:5260-5265.
23. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabási AL. 2007. The human disease network. Proc Natl Acad Sci USA 104:8685-8690.
24. Gonzalez-Garcia I, Sole RV, Costa J. 2002. Metapopulation dynamics and spatial heterogeneity in cancer. Proc Natl Acad Sci USA 99:13085-13089.
25. Greaves M. 2006. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer 6:193-203.
26. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O'Meara S, Vastrik I, Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J, Raine K, Richardson D, Shepherd R, Small A, Tofts C, Varian J, Webb T, West S, Widaa S, Yates A, Cahill DP, Louis DN, Goldstraw P, Nicholson AG, Brasseur F, Looijenga L, Weber BL, Chiew YE, DeFazio A, Greaves MF, Green AR, Campbell P, Birney E, Easton DF, Chenevix-Trench G, Tan MH, Khoo SK, Teh BT, Yuen ST, Leung SY, Wooster R, Futreal PA, Stratton MR. 2007. Patterns of somatic mutation in human cancer genome. Nature 446:153-158.
27. Hahn WC, Weinberg RA. 2002. Modeling the molecular circuitry of cancer. Nat Rev Cancer 2:331-341.
28. Harris H. 2005. A long view of fashions in cancer research. BioEssays 27:833-838.
29. He L, He X, Lowe SW, Hannon GJ. 2007. microRNAs join the p53 network-Another piece in the tumour-suppression puzzle. Nat Rev Cancer 7:819-822.
30. Heng HH. 2007a. Cancer genome sequencing: The challenges ahead. BioEssays 29:783-794.
31. Heng HH. 2007b. Elimination of altered karyotypes by sexual reproduction preserves species identity. Genome 50:517-524.
32. Heng HH. 2008a. The gene-centric concept: A new liability? Bioessays 30:196-197.
33. Heng HH. 2008b. The conflict between complex system and reductionism. JAMA 300:1580-1581.
34. Heng HH. 2009. The genome-centric concept: Re-synthesis of evolutionary theory. BioEssays 31:512-525.
35. Heng HH, Squire J, Tsui LC. 1992. High-resolution mapping of mammalian genes by in situ hybridization to free chromatin. Proc Natl Acad Sci USA 89:9509-9513.
36. Heng HH, Chamberlain JW, Shi XM, Spyropoulos B, Tsui LC, Moens PB. 1996. Regulation of meiotic chromatin loop size by chromosomal position. Proc Natl Acad Sci USA 93:2795-2800.
37. Heng HH, Spyropoulos B, Moens PB. 1997. FISH technology in chromosome and genome research. Bioessays 19:75-84.
38. Heng HH, Krawetz SA, Lu W, Bremer S, Liu G, Ye CJ. 2001. Re-defining the chromatin loop domain. Cytogenet Cell Genet 93:155-161.
39. Heng HH, Goetze S, Ye CJ, Liu G, Stevens JB, Bremer SW, Wykes SM, Bode J, Krawetz SA. 2004a. Chromatin loops are selectively anchored using scaffold/matrix-attachment regions. J Cell Sci 117:999-1008.
40. Heng HH, Stevens JB, Liu G, Bremer SW, Ye CJ. 2004b. Imaging genome abnormalities in cancer research. Cell Chromosome 3:1.
41. Heng HH, Liu G, Bremer S, Ye KJ, Stevens J, Ye CJ. 2006a. Clonal and non-clonal chromosome aberrations and genome variation and aberration. Genome 49:195-204.
42. Heng HH, Stevens JB, Liu G, Bremer SW, Ye KJ, Reddy PV, Wu GS, Wang YA, Tainsky MA, Ye CJ. 2006b. Stochastic cancer progression driven by non-clonal chromosome aberrations. J Cell Physiol 208:461-472.
43. Heng HH, Bremer SW, Stevens J, Ye KJ, Miller F, Liu G, Ye CJ. 2006c. Cancer progression by non-clonal chromosome aberrations. J Cell Biochem 98:1424-1435.
44. Heng HH, Stevens JB, Lawrenson L, Liu G, Ye KJ, Bremer SW, Ye CJ. 2008. Patterns of genome dynamics and cancer evolution. Cell Oncol 30:513-514.
45. Heppner GH. 1984. Tumor heterogeneity. Cancer Res 44:2259-2265.
46. Heppner GH, Miller FR. 1998. The cellular basis of tumor progression. Int Rev Cytol 177:1-56.
47. Hillenmeyer ME, Fung E, Wildenhain J, Pierce SE, Hoon S, Lee W, Proctor M, St Onge RP, Tyers M, Koller D, Altman RB, Davis RW, Nislow C, Giaever G. 2008. The chemical genomic portrait of yeast: uncovering a phenotype for all genes. Science 320:362-365.
48. Hochedlinger K, Blelloch R, Brennan C, Yamada Y, Kim M, Chin L, Jaenisch R. 2004. Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev 18:1875-1885.
49. Huang S. 2002. Histone methyltransferases, diet nutrients and tumor suppressors. Nature Rev Cancer 2:469-476.
50. Illmensee K, Mintz B. 1976. Totipotency and normal differentiation of single teratocarcinoma cells cloned by injection into blastocysts. Proc Natl Acad Sci USA 73:549-553.
51. Jaffe LF. 2005. A calcium-based theory of carcinogenesis. Adv Cancer Res 94:231-263.
52. Jones RG, Thompson CB. 2009. Tumor suppressors and cell metabolism: A recipe for cancer growth. Genes Dev 23:537-548.
53. Jones PA, Archer TK, Baylin SB, Beck S, Berger S, Bernstein BE, Carpten JD, Clark SJ, Costello JF, Doerge RW, Esteller M, Feinberg AP, Gingeras TR, Greally JM, Henikoff S, Herman JG, Jackson-Grusby L, Jenuwein T, Jirtle RL, Kim YJ, Laird PW, Lim B, Martienssen R, Polyak K, Stunnenberg H, Tlsty TD, Tycko B, Ushijima T, Zhu J, Pirrotta V, Allis CD, Elgin SC, Jones PA, Martienssen R, Rine J, Wu C. 2008a. American Association for Cancer Research Human Epigenome Task Force; European Union, Network of Excellence, Scientific Advisory Board. Moving AHEAD with an international human epigenome project. Nature 454:711-715.
54. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. 2008b. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801-1806.
55. Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH, Riethmüller G. 2002. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 360:683-689.
56. Kruse J, Gu W. 2008. SnapShot: p53 posttranslational modifications. Cell 133:930-930.
57. Kurdistani SK. 2007. Histone modifications as markers of cancer prognosis: A cellular view. Br J Cancer 97:1-5.
58. Kuukasjärvi T, Karhu R, Tanner M, Kähkönen M, Schäffer A, Nupponen N, Pennanen S, Kallioniemi A, Kallioniemi OP, Isola J. 1997. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 57:1597-1604.
59. Lujambio A, Esteller M. 2009. How epigenetics can explain human metastasis. A new role for microRNAs. Cell Cycle 8:377-382.
60. Ma L, Weinberg RA. 2008. Micromanagers of malignancy: Role of microRNAs in regulating metastasis. Trends Genet 24:448-456.
61. Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, Paulson TG, Blount PL, Risques RA, Rabinovitch PS, Reid BJ. 2006. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 38:468-473.
62. Mantovani A, Allavena P, Sica A, Balkwill F. 2008. Cancer-related inflammation. Nature 454:436-444.
63. Martien S, Abbadie C. 2007. Acquisition of oxidative DNA damage during senescence: the first step toward carcinogenesis? Ann NY Acad Sci 1119:51-63.
64. Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, Sivachenko A, Zhang X, Bernstein BE, Nusbaum C, Jaffe DB, Gnirke A, Jaenisch R, Lander ES. 2008. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454:766-770.
65. Merlo LM, Pepper JW, Reid BJ, Maley CC. 2006. Cancer as an evolutionary and ecological process. Nat Rev Cancer 6:924-935.
66. Mitelman F. 2000. Recurrent chromosome aberrations in cancer. Mutat Res 462:247-253.
67. Mohn F, Schubeler D. 2009. Genetics and epigenetics: Stability and plasticity during cellular differentiation. TIGS 25:129-136.
68. Mulero-Navarro S, Esteller M. 2008. Epigenetic biomarkers for human cancer: The time is now. Crit Rev Oncol Hematol 68:1-11.
69. Murray-Zmijewski F, Slee EA, Lu X. 2008. A complex barcode underlies the heterogeneous response of p53 to stress. Nat Rev Mol Cell Biol 9:702-712.
70. Nelson CM, Bissell MJ. 2006. Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol 22:287-309.
71. O'Neill LP, VerMilyea MD, Turner BM. 2006. Epigenetic characterization of the early embryo with a chromatin immunoprecipitation protocol applicable to small cell populations. Nat Genet 38:835-841.
72. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA, Jr., Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. 2008. An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812.
73. Resnick MA, Tomso D, Inga A, Menendez D, Bell D. 2005. Functional diversity in the gene network controlled by the master regulator p53 in humans. Cell Cycle 4:1026-1029.
74. Rodier F, Campisi J, Bhaumik D. 2007. Two faces of p53: Aging and tumor suppression. Nucleic Acids Res 35:7475-7484.
75. Rowley JD. 1988. The critical role of chromosome translocations in human leukemias. Annu Rev Genet 32:495-519.
76. Sharp PA. 2009. The centrality of RNA. Cell 136:577-580.
77. Shibata D, Tavaré S. 2006. Counting divisions in a human somatic cell tree: How, what and why? Cell Cycle 5:610-614.
78. Soto AM, Sonnenschein C. 2004. The somatic mutation theory of cancer: Growing problems with paradigm? BioEssays 26:1097-1107.
79. Soussi T, Wiman KG. 2007. Shaping genetic alterations in human cancer: The p53 mutation paradigm. Cancer Cell 12:303-312.
80. Soussi T, Ishioka C, Claustres M, Béroud C. 2006. Locus-specific mutation databases: Pitfalls and good practice based on the p53 experience. Nat Rev Cancer 6:83-90.
81. Stein GS, Zaidi SK, Stein JL, Lian JB, van Wijnen AJ, Montecino M, Young DW, Javed A, Pratap J, Choi JY, Ali SA, Pande S, Hassan MQ. 2009. Transcriptionfactor-mediated epigenetic control of cell fate and lineage commitment. Biochem Cell Biol 87:1-6.
82. Stevens JB, Liu G, Bremer SW, Ye KJ, Xu W, Xu J, Sun Y, Wu GS, Savasan S, Krawetz SA, Ye CJ, Heng HH. 2007. Mitotic cell death by chromosome fragmentation. Cancer Res 67:7686-7694.
83. Tsao JL, Yatabe Y, Salovaara R, Järvinen HJ, Mecklin JP, Aaltonen LA, Tavaré S, Shibata D. 2000. Genetic reconstruction of individual colorectal tumor histories. Proc Natl Acad Sci USA 97:1236-1241.
84. Valtieri M, Sorrentino A. 2008. The mesenchymal stromal cell contribution to homeostasis. J Cell Physiol 217:296-300.
85. Ventura A, Jacks T. 2009. MicroRNAs and cancer: Short RNAs go a long way. Cell 136:586-591.
86. Vogelstein B, Kinzler KW. 2004. Cancer genes and the pathways they control. Nat Med 10:789-799.
87. Whibley C, Pharoah PD, Hollstein M. 2009. p53 polymorphisms: cancer implications. Nat Rev Cancer. 9:95-107.
88. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein B. 2007. The genomic landscapes of human breast and colorectal cancers. Science 318:1108-1113.
89. Yamada Y, Jackson-Grusby L, Linhart H, Meissner A, Eden A, Lin H, Jaenisch R. 2005. Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. Proc Natl Acad Sci USA 102:13580-13585.
90. Ye CJ, Liu G, Bremer SW, Heng HH. 2007. The dynamics of cancer chromosomes and genomes. Cytogenet Genome Res 118:237-246.
91. Ye CJ, Stevens JB, Liu G, Bremer SW, Jaiswal AS, Ye KJ, Lin MF, Lawrenson L, Lancaster WD, Kurkinen M, Liao JD, Gairola CG, Shekhar MP, Narayan S, Miller FR, Heng HH. 2009. Genome based cell population heterogeneity promotes tumorigenicity: The evolutionary mechanism of cancer. J Cell Physiol 219:288-300.
92. Zaidi SK, Young DW, Javed A, Pratap J, Montecino M, van Wijnen A, Lian JB, Stein JL, Stein GS. 2007. Nuclear microenvironments in biological control and cancer. Nat Rev Cancer 7:454-463.
93. Zhu J, Yao X. 2009. Use of DNA methylation for cancer detection: Promises and challenges. Int J Biochem Cell Biol 41:147-154.